News & Resources / Press Releases

Veredus Laboratories Announces CE-IVD Marking of VereCoV™ Detection Kit for Diagnosis of COVID-19

Veredus Laboratories Pte Ltd “Veredus” today announced the CE-IVD marking of VereCoV™ Detection Kit for commercial launch in Europe. The test is intended for the qualitative detection of 2019 novel Coronavirus (2019-nCoV) also known as SARSCoV- 2 that causes COVID-19.

The kit was developed to provide an easy-to-use solution for clinical testing, public health surveillance and detection of the coronavirus from nasal or nasopharyngeal swab specimen to enable authorities to take appropriate actions. The test integrates PCR amplification and microarray for rapid qualitative detection of 2019-nCoV with the additional capability to detect a subset of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) simultaneously with the same test.

“We are ready to respond effectively to the needs of hospitals and reference laboratories by providing a quality molecular testing solution for the pandemic,” says Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.

Veredus Laboratories’ VereCoV™ Detection Kit receives Singapore HSA Provisional Authorisation for IVD use

Veredus Laboratories Pte Ltd “Veredus” has obtained the Provisional Authorisation from Singapore Health Sciences Authority (HSA) for its VereCoV™ Detection Kit following Veredus’ rapid launch of this kit as a “Research Use Only” (RUO) test earlier this year. With this Authorisation, VereCoV™ Detection Kit can be used directly by laboratories or hospitals to test patients for clinical diagnosis.

Veredus Laboratories Announces the Development of a Lab-on-Chip for the detection of 3 coronaviruses: MERS-CoV, SARS-CoV and 2019-nCoV

Veredus Laboratories Pte Ltd “Veredus”, a leading provider of innovative molecular diagnostic solutions, announced today the development of VereCoV detection kit, a portable Lab-on-Chip application capable of detecting the Middle-East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and 2019 Novel Coronavirus (2019-nCoV) i.e. Wuhan Coronavirus, in a single test.

Veredus Laboratories launches VereBeef™ Detection Kit for the detection of multiple pathogens in raw beef trim

VereBeef™ Detection Kit used in conjunction with the VerePLEX™ Biosystem is best described as an integration of both multiplex PCR and microarray on a Lab-on-Chip platform (VereChip™). It was specifically developed for the qualitative detection and differentiation of Escherichia coli (E. coli) O157:H7, E. coli O26, E. coli O45, E. coli O103, E. coli O111, E. coli O121, E. coli O145, STEC virulence factors (stx1A, stx2A, eae), and Salmonella spp. in a single test using raw beef trim samples.

VereBeef Press Release Final (Singapore)

Veredus Laboratories Pte Ltd is pleased to announce its acquisition by SEKISUI CHEMICAL CO., LTD.

Veredus Laboratories Pte Ltd is pleased to announce its acquisition by SEKISUI CHEMICAL CO., LTD1.

Founded in 2003, Veredus Laboratories Pte Ltd (hereinafter, “Veredus”) specializes in the development, manufacturing and marketing of innovative multiplexed molecular solutions in the clinical, specialty, and custom testing markets based on STMicroelectronics’ Lab-on-Chip platform. The Lab-on-Chip platform, also known as the VerePLEX™ Biosystem, combines Micro-Electro Mechanical Systems (MEMS) with micro-fluidics to integrate multiplexed DNA amplification with microarray detection for rapid, cost-effective, and accurate analysis of biological materials.

With this acquisition, Veredus will continue to carry its own product line and also welcome the medical products from SEKISUI MEDICAL CO., LTD., a company which is 100% subsidiary of SEKISUI CHEMICAL CO., LTD.

Dr Rosemary Tan will continue to lead Veredus as its Chief Executive Officer, and Veredus remains fully committed in bringing innovative technologies and quality products to our customers.

1Refer to Official Press Release by SEKISUI CHEMICAL CO., LTD, dated 3rd April, 2018

VereFever™ Lab-On-Chip for the Simultaneous Detection of Tropical Infectious Diseases including Dengue, Zika, Malaria and Chikungunya,

VereFever™ is able to detect, differentiate and identify 7 different major tropical diseases from a single blood sample, including Malaria, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis and Zika by using the STMicroelectronics proprietary Lab-on-Chip platform that integrates two powerful molecular biological applications, Polymerase Chain Reaction (PCR) and a microarray.

More information

AVA and Veredus Laboratories announces the launch of World’s First Poultry Biochip “VereVet”

The Agri-Food and Veterinary Authority of Singapore (AVA) and Veredus Laboratories has jointly launched VereVet™, a portable Lab-on-Chip application that is able to detect, differentiate and identify nine major poultry infectious disease agents from one sample in one single test.

More information

Veredus Laboratories’ VerePLEX™ Biosystem Deployed at FIFA World Cup 2014 for Biosurveillance.

VerePLEX™ Biosystem has been selected by the Brazilian civil security forces as a system to monitor and identify potential biological threats during the  FIFA World Cup 2014.

More information

Veredus Announces VereMERS™ for detection of MERS-CoV.

Veredus has successfully developed VereMERS™, a Lab-on-Chip application that is able to detect, from a sequence perspective, Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

More information

A*STAR and Veredus Laboratories Create Market’s First Lab-on-Chip for the Detection of Multiple Tropical Infectious Diseases.

The Agency for Science, Technology and Research (A*STAR) and VeredusLaboratories announced the launch of VereTrop™, the first biochip in the molecular diagnostics market that can identify 13 different major tropical diseases, from a single blood sample.

More information